LLY

1,031.07

-1.11%↓

JNJ

245.04

-0.21%↓

ABBV

226.71

-0.78%↓

NVS

167.17

+0.28%↑

MRK

122.88

-1.14%↓

LLY

1,031.07

-1.11%↓

JNJ

245.04

-0.21%↓

ABBV

226.71

-0.78%↓

NVS

167.17

+0.28%↑

MRK

122.88

-1.14%↓

LLY

1,031.07

-1.11%↓

JNJ

245.04

-0.21%↓

ABBV

226.71

-0.78%↓

NVS

167.17

+0.28%↑

MRK

122.88

-1.14%↓

LLY

1,031.07

-1.11%↓

JNJ

245.04

-0.21%↓

ABBV

226.71

-0.78%↓

NVS

167.17

+0.28%↑

MRK

122.88

-1.14%↓

LLY

1,031.07

-1.11%↓

JNJ

245.04

-0.21%↓

ABBV

226.71

-0.78%↓

NVS

167.17

+0.28%↑

MRK

122.88

-1.14%↓

Search

ResMed Inc

Abrir

SetorSaúde

252.23 0.31

Visão Geral

Variação de preço das ações

24h

Atual

Mín

249.71

Máximo

252.29

Indicadores-chave

By Trading Economics

Rendimento

44M

393M

Vendas

87M

1.4B

P/E

Médio do Setor

25.005

110.024

Rendimento de Dividendos

0.92

Margem de lucro

27.593

Funcionários

10,600

EBITDA

63M

566M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+15.28% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

0.92%

2.26%

Próximos Ganhos

22 de abr. de 2026

Próxima data de dividendos

19 de mar. de 2026

Próxima data de ex-dividendo

7 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-426M

37B

Abertura anterior

251.92

Fecho anterior

252.23

Sentimento de Notícias

By Acuity

17%

83%

23 / 351 Ranking em Healthcare

ResMed Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

24 de fev. de 2026, 23:07 UTC

Ganhos

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24 de fev. de 2026, 23:01 UTC

Ganhos

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24 de fev. de 2026, 22:59 UTC

Ganhos

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

24 de fev. de 2026, 22:42 UTC

Ganhos

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

24 de fev. de 2026, 22:24 UTC

Aquisições, Fusões, Aquisições de Empresas

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

24 de fev. de 2026, 23:46 UTC

Conversa de Mercado

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

24 de fev. de 2026, 23:36 UTC

Conversa de Mercado

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

24 de fev. de 2026, 23:30 UTC

Conversa de Mercado

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

24 de fev. de 2026, 23:20 UTC

Conversa de Mercado

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

24 de fev. de 2026, 23:20 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

24 de fev. de 2026, 23:16 UTC

Ganhos

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

24 de fev. de 2026, 23:13 UTC

Ganhos

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

24 de fev. de 2026, 23:12 UTC

Ganhos

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

24 de fev. de 2026, 23:10 UTC

Ganhos

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

24 de fev. de 2026, 23:10 UTC

Ganhos

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

24 de fev. de 2026, 23:08 UTC

Ganhos

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

24 de fev. de 2026, 23:07 UTC

Ganhos

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

24 de fev. de 2026, 22:52 UTC

Ganhos

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24 de fev. de 2026, 22:46 UTC

Ganhos

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24 de fev. de 2026, 22:31 UTC

Aquisições, Fusões, Aquisições de Empresas

Warner Receives New Bid From Paramount -- 3rd Update

24 de fev. de 2026, 22:29 UTC

Ganhos

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

24 de fev. de 2026, 22:28 UTC

Ganhos

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

24 de fev. de 2026, 22:27 UTC

Ganhos

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

24 de fev. de 2026, 22:27 UTC

Ganhos

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

24 de fev. de 2026, 22:25 UTC

Ganhos

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

24 de fev. de 2026, 22:24 UTC

Ganhos

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

24 de fev. de 2026, 22:23 UTC

Ganhos

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

24 de fev. de 2026, 22:22 UTC

Ganhos

Woolworths Interim Dividend 45 Australian Cents/Share

24 de fev. de 2026, 22:22 UTC

Ganhos

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

24 de fev. de 2026, 22:21 UTC

Ganhos

Woolworths 1H Statutory Net Profit A$374 Mln, Down 49.4%

Comparação entre Pares

Variação de preço

ResMed Inc Previsão

Preço-alvo

By TipRanks

15.28% parte superior

Previsão para 12 meses

Média 300.64 USD  15.28%

Máximo 345 USD

Mínimo 265 USD

Com base em 13 analistas de Wall Street que oferecem metas de preço de 12 meses para ResMed Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

13 ratings

8

Comprar

5

Manter

0

Vender

Sentimento

By Acuity

23 / 351 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre ResMed Inc

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
help-icon Live chat